MX387490B - Uso del agente de refuerzo del receptor del ácido gamma-aminobutírico tipo a (gabaa) en la preparación de un sedante y medicamento anestésico. - Google Patents

Uso del agente de refuerzo del receptor del ácido gamma-aminobutírico tipo a (gabaa) en la preparación de un sedante y medicamento anestésico.

Info

Publication number
MX387490B
MX387490B MX2017002896A MX2017002896A MX387490B MX 387490 B MX387490 B MX 387490B MX 2017002896 A MX2017002896 A MX 2017002896A MX 2017002896 A MX2017002896 A MX 2017002896A MX 387490 B MX387490 B MX 387490B
Authority
MX
Mexico
Prior art keywords
sedative
preparation
reinforcing agent
medicament
gabaa receptor
Prior art date
Application number
MX2017002896A
Other languages
English (en)
Other versions
MX2017002896A (es
Inventor
Fangqiong Li
Fujun Cheng
Hong Mu
Honghu Li
Jianyu Liu
Pangke Yan
Linlin Qin
Qingyang Yu
Yan Yu
Yi Mo
Yuquan Zhang
Ziwei Zhao
Original Assignee
Haisco Innovative Pharmaceutical Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Innovative Pharmaceutical Pte Ltd filed Critical Haisco Innovative Pharmaceutical Pte Ltd
Publication of MX2017002896A publication Critical patent/MX2017002896A/es
Publication of MX387490B publication Critical patent/MX387490B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está relacionada a una preparación farmacéutica de un compuesto de la fórmula (I) o estereoisómero, sal farmacéuticamente aceptable, o profármaco del mismo, y un método novedoso para la anestesia general o sedación en mamíferos; también se proporcionan kits y productos fabricados del medicamento y la composición farmacéutica y un método para utilizar el medicamento y la composición farmacéutica; R1, R2 y n son como se definen en la descripción. (ver Fórmula).
MX2017002896A 2014-09-04 2015-08-28 Uso del agente de refuerzo del receptor del ácido gamma-aminobutírico tipo a (gabaa) en la preparación de un sedante y medicamento anestésico. MX387490B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410449723 2014-09-04
CN201410449571 2014-09-04
PCT/CN2015/088341 WO2016034079A1 (zh) 2014-09-04 2015-08-28 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途

Publications (2)

Publication Number Publication Date
MX2017002896A MX2017002896A (es) 2017-05-30
MX387490B true MX387490B (es) 2025-03-18

Family

ID=55439127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002896A MX387490B (es) 2014-09-04 2015-08-28 Uso del agente de refuerzo del receptor del ácido gamma-aminobutírico tipo a (gabaa) en la preparación de un sedante y medicamento anestésico.

Country Status (16)

Country Link
US (1) US10729666B2 (es)
EP (1) EP3189834B1 (es)
JP (1) JP6502480B2 (es)
KR (1) KR102056649B1 (es)
CN (1) CN105579034B (es)
AU (1) AU2015311394B2 (es)
BR (1) BR112017004448B1 (es)
CA (1) CA2959812C (es)
EA (1) EA035649B1 (es)
ES (1) ES2973259T3 (es)
MX (1) MX387490B (es)
MY (1) MY194087A (es)
PT (1) PT3189834T (es)
TW (1) TWI650119B (es)
WO (1) WO2016034079A1 (es)
ZA (1) ZA201701785B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194087A (en) 2014-09-04 2022-11-11 Haisco Innovative Pharmaceutical Pte Ltd Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
CN109071392B (zh) * 2016-06-08 2020-10-02 四川海思科制药有限公司 苯环衍生物及其制备方法和在医药上的应用
WO2018014770A1 (zh) * 2016-07-22 2018-01-25 四川海思科制药有限公司 一种苯酚衍生物和依托咪酯的药物组合物、药物制剂及其用途
CN108017559B (zh) * 2016-11-04 2020-08-04 四川海思科制药有限公司 苯环衍生物及其在医药上的应用
CN108069833B (zh) * 2016-11-15 2020-11-06 四川海思科制药有限公司 苯并四环衍生物及其制备方法和在医药上的应用
EP3498273A1 (en) * 2017-12-14 2019-06-19 Universität Wien Pharmaceutical composition for modulating the response of a gaba-a receptor
CN110063947A (zh) * 2018-01-24 2019-07-30 四川海思科制药有限公司 苯酚衍生物用于制备麻醉药物中的用途
CN108653446B (zh) * 2018-07-26 2019-05-28 四川大学华西医院 一种表面麻醉药物组合物、微乳及其制备方法和应用
US11872237B2 (en) * 2018-12-28 2024-01-16 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition and preparation method thereof
CN109793709A (zh) * 2019-02-22 2019-05-24 青岛农业大学 一种斑海豹用复方注射剂及其制备方法
CN110361472B (zh) * 2019-07-29 2022-04-29 武汉嘉诺康医药技术有限公司 一种米库氯铵中间体miv-g异构体的hplc检测方法
CN120827516A (zh) * 2020-05-29 2025-10-24 西藏海思科制药有限公司 一种药物制剂及其制备方法
CN111759857A (zh) * 2020-06-30 2020-10-13 宁波市微循环与莨菪类药研究所 Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用
TW202221720A (zh) 2020-08-03 2022-06-01 大陸商四川海思科製藥有限公司 確定異丙酚及其衍生物群體藥代動力學模型的方法及系統
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN113081964B (zh) * 2021-04-14 2022-09-02 广州市力鑫药业有限公司 一种盐酸戊乙奎醚纳米药物及其制备方法
CN114129578A (zh) * 2021-09-28 2022-03-04 瑞普（天津）生物药业有限公司 甲磷丙泊酚钠在制备宠物麻醉、镇静药物中的应用
CN114931551B (zh) * 2022-05-11 2023-04-25 四川科瑞德制药股份有限公司 一种25℃储存稳定的米库氯铵注射液及其制备方法和用途
CN116570718B (zh) * 2023-04-26 2025-09-30 四川大学华西医院 一种包含局麻药和磷丙泊酚二钠的药物组合物、其制备方法和用途以及一种联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA911845A (en) 1972-10-10 G. Breiling Hans Expanding temperature sensor for medical appliances
US3816624A (en) * 1970-06-17 1974-06-11 Glaxo Lab Ltd Anaesthetic steroids
US6254853B1 (en) * 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
EP2152651B1 (en) * 2007-05-09 2012-01-04 Pharmacofore, Inc. Therapeutic compounds
KR100913600B1 (ko) 2007-09-28 2009-08-26 주식회사 한메드 근력 측정기
CN101199480B (zh) 2007-12-11 2010-07-28 西安力邦医药科技有限责任公司 一种含镇痛药的复方丙泊酚脂肪乳注射剂及制备方法
US20120283335A1 (en) 2008-05-12 2012-11-08 Jenkins Thomas E Analogs of Propofol, Preparation Thereof and Use as Anesthetics
GB0822486D0 (en) 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
KR101871732B1 (ko) 2013-05-09 2018-06-27 스촨 하이스코 파마수티컬 씨오., 엘티디 페놀유도체, 이의 제조방법 및 의약에서의 이의 용도
MY194087A (en) 2014-09-04 2022-11-11 Haisco Innovative Pharmaceutical Pte Ltd Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament

Also Published As

Publication number Publication date
US10729666B2 (en) 2020-08-04
JP2017525743A (ja) 2017-09-07
CN105579034B (zh) 2018-05-15
MX2017002896A (es) 2017-05-30
MY194087A (en) 2022-11-11
BR112017004448A2 (pt) 2018-07-03
US20170290781A1 (en) 2017-10-12
PT3189834T (pt) 2024-03-15
TW201613567A (en) 2016-04-16
EP3189834A4 (en) 2018-06-06
EA201790525A1 (ru) 2017-08-31
TWI650119B (zh) 2019-02-11
EA035649B1 (ru) 2020-07-21
ZA201701785B (en) 2018-05-30
AU2015311394A1 (en) 2017-03-09
CA2959812A1 (en) 2016-03-10
KR102056649B1 (ko) 2019-12-17
WO2016034079A1 (zh) 2016-03-10
EP3189834A1 (en) 2017-07-12
CN105579034A (zh) 2016-05-11
BR112017004448B1 (pt) 2024-01-09
ES2973259T3 (es) 2024-06-19
CA2959812C (en) 2021-11-23
EP3189834B1 (en) 2024-01-17
HK1221897A1 (zh) 2017-06-16
JP6502480B2 (ja) 2019-04-17
AU2015311394B2 (en) 2018-11-08
KR20170048543A (ko) 2017-05-08

Similar Documents

Publication Publication Date Title
TW201613567A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
NZ747259A (en) Soluble c5ar antagonists
PH12018500591B1 (en) Heterocyclic compounds and uses thereof
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MY175854A (en) Novel quinolone derivatives
MX393820B (es) Derivado de ?-aminoácido tricíclico fusionado, método de preparación, y uso médico del mismo.
TW201613864A (en) Novel compounds
MY187614A (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12016501903B1 (en) Novel fused imidazobenzothiazole compounds
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
EA201792234A1 (ru) Новые соединения пиридиния
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
UY36084A (es) Activadores de herg policíclicos
MX2018015990A (es) Compuestos terapeuticos.
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety